Muscle Performance in Patients With Crohnʼs Disease in Clinical Remission

Wiroth, Jean-Baptiste; Filippi, Jérôme; Schneider, S.; Al-Jaouni, Rima; Horvais, Nicolas; Gavarry, Olivier; Bermon, Stéphane; Hébuterne, Xavier

doi:10.1097/01.mib.0000160810.76729.9c

Cited by 80 publications

(117 citation statements)

References 38 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In this issue, Salacinski et al [5] have objectively demonstrated reduced lower limb muscle strength in subjects with Crohn's disease (CD) compared to healthy controls, confirming the work of previous studies [6,7]. However, the study was unable to show that this reduced strength was directly attributable to lower vitamin D (25-(OH) or vitamin D3) levels in CD subjects as originally hypothesized.…”

Section: Introductionsupporting

confidence: 56%

Maintaining Muscle Strength in Crohn’s Disease: Can a Vitamin D Daily Keep Muscle Loss Away?

Langenberg

2013

Dig Dis Sci

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 56%

Maintaining Muscle Strength in Crohn’s Disease: Can a Vitamin D Daily Keep Muscle Loss Away?

Langenberg

2013

Dig Dis Sci

View full text Add to dashboard Cite

“…Compared with healthy controls in Crohn's disease skeletal muscle mass and strength are reduced (87)(88)(89) and muscle fatigue is increased (90) . Fatigue is a major concern in Crohn's disease (91)(92)(93)(94) with two of five patients reporting that it negatively impacts their QoL, even in remission (95) .…”

Section: Clinical Studies; Association Between 25-hyroxyvitamin D Levmentioning

confidence: 95%

Optimal vitamin D levels in Crohn's disease: a review

Raftery

O’Sullivan

2014

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Vitamin D deficiency is common among patients with Crohn's disease. Serum 25-hydroxyvitamin D (25(OH)D) is the best measure of an individual's vitamin D status and current cut-off ranges for sufficiency are debatable. Several factors contribute to vitamin D deficiency in Crohn's disease. These include inadequate exposure to sunlight, inadequate dietary intake, impaired conversion of vitamin D to its active metabolite, increased catabolism, increased excretion and genetic variants in vitamin D hydroxylation and transport. The effects of low 25(OH)D on outcomes other than bone health are understudied in Crohn's disease. The aim of the present review is to discuss the potential roles of vitamin D and the possible levels required to achieve them. Emerging evidence suggests that vitamin D may have roles in innate and adaptive immunity, in the immune-pathogenesis of Crohn's disease, prevention of Crohn's disease-related hospitalisations and surgery, in reducing disease severity and in colon cancer prevention. The present literature appears to suggest that 25(OH)D concentrations of ≥75 nmol/l may be required for non-skeletal effects; however, further research on optimal levels is required.

show abstract

“…We also identified several pathways related with cellular catabolic process and muscle development. Abnormal cellular metabolic process could cause increased energy expenditure, which are typically shown in patients with CD and could further alter muscle mass and function with persist nutritional deficiencies [40]. However, given the fact that there still lacks a complete understanding of the etiology of CD, it is difficult to provide a conclusive evaluation, which will be studied in our future research.…”

Section: Resultsmentioning

confidence: 99%

Supervised categorical principal component analysis for genome-wide association analyses

et al. 2014

View full text Add to dashboard Cite

In order to have a better understanding of unexplained heritability for complex diseases in conventional Genome-Wide Association Studies (GWAS), aggregated association analyses based on predefined functional regions, such as genes and pathways, become popular recently as they enable evaluating joint effect of multiple Single-Nucleotide Polymorphisms (SNPs), which helps increase the detection power, especially when investigating genetic variants with weak individual effects. In this paper, we focus on aggregated analysis methods based on the idea of Principal Component Analysis (PCA). The past approaches using PCA mostly make some inherent genotype data and/or risk effect model assumptions, which may hinder the accurate detection of potential disease SNPs that influence disease phenotypes. In this paper, we derive a general Supervised Categorical Principal Component Analysis (SCPCA), which explicitly models categorical SNP data without imposing any risk effect model assumption. We have evaluated the efficacy of SCPCA with the comparison to a traditional Supervised PCA (SPCA) and a previously developed Supervised Logistic Principal Component Analysis (SLPCA) based on both the simulated genotype data by HAPGEN2 and the genotype data of Crohn's Disease (CD) from Wellcome Trust Case Control Consortium (WTCCC). Our preliminary results have demonstrated the superiority of SCPCA over both SPCA and SLPCA due to its modeling explicitly designed for categorical SNP data as well as its flexibility on the risk effect model assumption.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2164-15-S1-S10) contains supplementary material, which is available to authorized users.

show abstract

Muscle Performance in Patients With Crohnʼs Disease in Clinical Remission

Cited by 80 publications

References 38 publications

Maintaining Muscle Strength in Crohn’s Disease: Can a Vitamin D Daily Keep Muscle Loss Away?

Maintaining Muscle Strength in Crohn’s Disease: Can a Vitamin D Daily Keep Muscle Loss Away?

Optimal vitamin D levels in Crohn's disease: a review

Supervised categorical principal component analysis for genome-wide association analyses

Contact Info

Product

Resources

About